Loading clinical trials...

Atrial Fibrillation in Active Cancer Patients | Clinical Trials | Clareo Health

RECRUITING

Atrial Fibrillation in Active Cancer Patients

Multicenter International Prospective Registry to Identify Major Cardiovascular Events Associated With the Occurrence of Atrial Fibrillation in Active Cancer Patients

NCT04696081•University Hospital, Caen

View on ClinicalTrials.gov

Summary

Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•adult patients
•outpatients or hospitalized patients
•with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)
•at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)
•in sinus rhythm at the time of cancer diagnosis

Exclusion Criteria

•patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)
•history of long-standing persistant or permanent AF prior to cancer diagnosis

Locations (1)

Alexandre

Caen, Normandy, France

Key Dates

Start Date

September 1, 2021

Primary Completion Date

September 1, 2025

Completion Date

January 1, 2026

Last Updated

August 9, 2024

Enrollment

1,000

ESTIMATED participants

Conditions

CancerDrug ToxicityAtrial FibrillationCardiovascular Complication

Interventions

occurence of atrial fibrillation

OTHER

Contacts

Joachim Alexandre, MD, PhD

CONTACT

+330231064770 alexandre-j@chu-caen.fr

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

NCT05884320

GlandSalivary Gland Cancers

View study

RECRUITINGPHASE3

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Atrial Fibrillation in Active Cancer Patients

Inclusion Criteria

Exclusion Criteria

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)